Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 0.35 is 42% below its 5-year average of 0.61, around the middle of its 5-year range (-2.15–3.41).
135.18% above its 12-month average of -0.99.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.12.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 37 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T22:38:16.333Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
0.35
EARNINGS PER SHARE (EPS) AVG TTM
-0.99
EARNINGS PER SHARE (EPS) AVG 3Y
-0.18
EARNINGS PER SHARE (EPS) AVG 5Y
0.61
EARNINGS PER SHARE (EPS) AVG 10Y
0.12
EARNINGS PER SHARE (EPS) AVG 15Y
-0.69
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+135.18%
CURRENT VS 3Y AVG
+291.78%
CURRENT VS 5Y AVG
-42.15%
CURRENT VS 10Y AVG
+194.23%
CURRENT VS 15Y AVG
+150.67%
CURRENT VS 20Y AVG
N/A
Pacira BioSciences, Inc.
Market Cap
$973.93M
Earnings Per Share (EPS)
0.35
TTM Avg
-0.99
3Y Avg
-0.18
5Y Avg
0.61
Market Cap
$978.09M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
Earnings Per Share (EPS)
0.71
TTM Avg
-1.77
3Y Avg
-1.98
5Y Avg
-1.86
Market Cap
$982.46M
Earnings Per Share (EPS)
-2.97
TTM Avg
-9.41
3Y Avg
-6.16
5Y Avg
-6.16
Market Cap
$992.14M
Earnings Per Share (EPS)
N/A
TTM Avg
-52.25
3Y Avg
-46.52
5Y Avg
-41.75
Market Cap
$953.81M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.23
3Y Avg
-0.94
5Y Avg
-0.94
Market Cap
$952.91M
Earnings Per Share (EPS)
-0.58
TTM Avg
-0.51
3Y Avg
-0.40
5Y Avg
-0.46
Market Cap
$996.65M
Earnings Per Share (EPS)
-1.94
TTM Avg
-1.73
3Y Avg
-1.92
5Y Avg
-1.76
Market Cap
$998.69M
Earnings Per Share (EPS)
-3.37
TTM Avg
-3.42
3Y Avg
-2.02
5Y Avg
-1.79
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | $973.93M | 0.35 | -0.99 | -0.18 | 0.61 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 0.71 | -1.77 | -1.98 | -1.86 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | -2.97 | -9.41 | -6.16 | -6.16 |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | N/A | -52.25 | -46.52 | -41.75 |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | -1.05 | -1.23 | -0.94 | -0.94 |
| Savara Inc. (SVRA)vs › | $952.91M | -0.58 | -0.51 | -0.40 | -0.46 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | -1.94 | -1.73 | -1.92 | -1.76 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | -3.37 | -3.42 | -2.02 | -1.79 |
| Immatics N.V. (IMTX)vs › | $1.01B | -1.84 | -0.83 | -0.99 | -2.01 |
Trailing EPS (TTM)
$0.35
Forward EPS (Est.)
$2.89
P/E Ratio
70.5
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.16 |
| 2024-12-31 | -2.15 |
| 2023-12-31 | 0.91 |
| 2022-12-31 | 0.35 |
| 2021-12-31 | 0.95 |
| 2020-12-31 | 3.41 |
| 2019-12-31 | -0.27 |
| 2018-12-31 | -0.01 |
| 2017-12-31 | -1.07 |
| 2016-12-31 | -1.02 |
| 2015-12-31 | 0.05 |
| 2014-12-31 | -0.39 |
| 2013-12-31 | -1.93 |
| 2012-12-31 | -1.72 |
| 2011-12-31 | -2.64 |
| 2010-12-31 | -1.58 |
| 2009-12-31 | -55.32 |
| 2008-12-31 | -79.23 |
(FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown Quote observation: 2026-10-06T22:38:16.333Z. Historical observations retain their original dates. Historical series through 2022-02-28.
